Abstract
IntroductionEstimation of hepatitis B (HBV) viral load (VL) is critical in hepatitis-B cascade-of-care and at present there is no point of care (POC) molecular assay available for the same. This study evaluated the performance of a new near point of care molecular assay Xpert HBV- VL assay against the approved assays. Materials & methodsIn this study 172 archived previously tested samples, were simultaneously re-tested for HBV DNA on 3 real-time PCR assays: Abbott Real-Time HBV, Roche TaqMan® HBV and Xpert HBV assay. ResultsOut of 172 samples, 119 were previously positive for HBV DNA with a median VL 4.46 (IQR: 1–8.76)log10IU/mL and 53 were HBV DNA negative. Genotyping could be done in 95 (79.8 %) samples and genotype D (83; 87.3 %) was the commonest type. The Xpert assay demonstrated a good correlation with Abbott (R2 = 0.94) and Roche (R2 = 0.96). On comparison, the mean difference with 95 % Confidence Interval of Xpert assay was −0.018 and −0.043 log10 IU/mL with Abbott and Roche assay, respectively. The overall sensitivity, specificity, negative predictive value, and positive predictive value of the Xpert assay was found 97.5 %, 100 %, 94.65 & 100 % respectively. ConclusionXpert HBV-VL assay which has a potential for near point of care molecular testing has shown excellent performance and found to be a reliable method for HBV DNA quantification.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
